Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats
T. Huo, R. Barth, W. Yang, J. Nakkula R., R. Koynova, B. Tenchov, R. Chaudhury A., L. Agius, T. Boulkas, H. Elleaume, et al.

To cite this version:
T. Huo, R. Barth, W. Yang, J. Nakkula R., R. Koynova, et al.. Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats. PLoS ONE, Public Library of Science, 2012, 7 (11), pp.e48752. 10.1371/journal.pone.0048752. hal-00850702

HAL Id: hal-00850702
https://hal.archives-ouvertes.fr/hal-00850702
Submitted on 8 Aug 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Preparation, Biodistribution and Neurotoxicity of Liposomal Cisplatin following Convection Enhanced Delivery in Normal and F98 Glioma Bearing Rats

Tianyao Huo1*, Rolf F. Barth1*, Weilian Yang1, Robin J. Nakkula1, Rumiana Koynova2, Boris Tenchov2, Abhik Ray Chaudhury1, Lawrence Agius3, Teni Boulikas4, Helene Elleaume5, Robert J. Lee2

1 Department of Pathology, The Ohio State University, Columbus, Ohio, United States of America, 2 Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America, 3 Department of Pathology, Mater Dei Hospital and University of Malta Medical School, Msida, Malta, 4 Regulon Inc., Mountain View, California, United States of America, 5 European Synchrotron Radiation Facility, Grenoble, France

Abstract

The purpose of this study was to evaluate two novel liposomal formulations of cisplatin as potential therapeutic agents for treatment of the F98 rat glioma. The first was a commercially produced agent, LipoplatinTM, which is currently in a Phase III clinical trial for treatment of non-small cell lung cancer (NSCLC). The second, produced in our laboratory, was based on the ability of cisplatin to form coordination complexes with lipid cholesteryl hemisuccinate (CHEMS). The in vitro tumoricidal activity of the former previously has been described in detail by other investigators. The CHEMS liposomal formulation had a 1000-fold increase in the mean survival time (MST) of F98 glioma bearing rats with a subset of cured animals produced a 2.5 to 3.6 fold increase in the mean survival time (MST) of F98 glioma bearing rats. Neurotoxicologic studies were carried out in non-tumor bearing Fischer rats following i.c. convection enhanced delivery (CED) of F98 glioma bearing rats. The authors' data provide a very strong cautionary note regarding its intracerebral delivery. In other words, it does not support this route of administration for the drug, LipoplatinTM, which is manufactured by Regulon, Inc. Dr. Teni Boulikas, a co-author of this manuscript, is Chairman of the Board and Chief Executive Officer of Regulon, Inc. Based on ongoing clinical trials, it appears to have a number of significant advantages over the free drug cisplatin, when administered intravenously. The fact that Dr. Boulikas is Chairman of the Board and Chief Executive Officer of Regulon, Inc. does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Introduction

Platinum containing drugs are widely used chemotherapeutic agents for the treatment of a variety of human cancers [1,2]. However, their renal, gastro-intestinal and neurotoxicity, rapid binding to plasma proteins, and poor penetration of the central nervous system (CNS) have limited their use for the treatment of brain tumors [2–4]. We recently have reported that intracerebral (i.c.) convection enhanced delivery (CED) or osmotic pump infusion of carboplatin in combination with radiotherapy (RT), produced a 2.5 to 3.6 fold increase in the mean survival time (MST) of F98 glioma bearing rats with a subset of cured animals [5]. However, the wide range of survival times (37–180 days) suggested that there was non-homogenous distribution of the drug within the tumors. This occurred despite the fact that i.c. CED of 20 µg of carboplatin resulted in a tumor drug concentration (10.4 µg/g) equivalent to that observed following i.v. administration of a 1000× greater dose (20 mg or 20,000 µg) to F98 glioma bearing rats. These observations suggested to us that a liposomal formulation of the drug might result in not only more sustained release, but also improved microdistribution within the tumor [6,7].

Liposomes have been used clinically to deliver a variety of anticancer drugs including cisplatin [8–11], but not for the treatment of brain tumors. Bankiewicz [12–14] and Dickinson [15,16] and their research teams have carried out extensive studies in rodents, dogs and primates to evaluate CED of liposomes, loaded with either tracers or therapeutic agents for the treatment
of brain tumors. Loading cisplatin into liposomes potentially could reduce its systemic toxicity and improve its microdistribution within brain tumors following CED [17]. For the design and preparation of liposomal nanovehicles, it is important to achieve a balance between their stability, encapsulation efficiency, drug release, i.e., drug distribution, and tumoricidal activity. This is especially true if they are to be used for the treatment of brain tumors, where the blood-brain barrier (BBB) severely limits tumor uptake following systemic administration [18]. This could be circumvented by directly administering them i.e. by means of CED, if the delivery parameters can be optimized [19]. Readers interested in more detailed information relating to CED of liposomes for the treatment of brain tumors are referred to a recent review on this topic [20].

In the present study we initially evaluated a proprietary liposomal formulation of cisplatin (Lipoplatin™, Regulon Inc. Mountain View, CA) [6–11] and their “hollow” counterparts in non-tumor bearing Fischer rats. These unexpectedly proved to be highly neurotoxic, and served as an impetus for us to develop a formulation that would be better tolerated following i.c. CED. In this report we describe a novel liposomal cisplatin formulation that we have prepared, which was based on the ability of cisplatin to form coordination complexes with lipid cholesteryl hemisuccinate (CHEMS) [21]. These liposomes showed increased in vitro cytotoxicity against F98 glioma cells compared to free cisplatin and tumor retention in F98 glioma bearing rats. However, neurotoxicologic studies, carried out in non-tumor bearing animals, showed that the CHEMS liposomes and their “hollow” counterparts produced a variety of neuropathologic changes ranging from minimal to severe. These findings indicated that they were not suitable for therapy studies and that further work will be required to produce liposomal cisplatin containing nanovehicles that will be well tolerated when administered i.e. by CED to F98 glioma bearing rats.

Materials and Methods

Chemicals

Egg yolk phosphatidylcholine (egg PC), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glyc-]

Preparation and Characterization of Lipoplatin™ and CHEMS Liposomes

Lipoplatin™ is a liposomal formulation of cisplatin, composed of the lipids 1, 2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycer-ol) (sodium salt), also known as dipalmitoyl phosphatidyl glycerol (DPPG, MW 745Da), soy phosphatidyl choline (SPC-3, MW 790 Da), cholesterol (MW, 386.66 Da) and mPEG-DSPE. It was produced in two steps: First liposomes composed of SPC-3, cholesterol and mPEG-DSPE were prepared. Second, reverse micelles between the cisplatin dihydroxy form (positively charged) and DPPG (negatively charged) were formed in an ethanolic solution, which then was engulfed by the liposomes from step 1 by mixing them under proprietary conditions. The resulting preparation was a sterile, non-pyrogenic opaque liquid intended for intravenous injection [9]. The “hollow” Lipoplatin liposomes were produced in a similar manner but did not contain any cisplatin.

To prepare CHEMS liposomes egg PC, CHEMS and mPEG-DSPE (20:10:1, w/w) were mixed in chloroform and dried into a thin film by evaporating the bulk of the solvent under nitrogen, and the residual solvent was removed under vacuum. A 10% by weight (wt%) aqueous sucrose solution (pH 8.0), was added and the lipid film was hydrated overnight at ambient temperature and finally for 1 h at 37°C. The lipid dispersion was sonicated for 1 min in a bath sonicator to generate liposomes, and then processed by a high-pressure EmulsiFlex-C5 homogenizer (Avet- tin, Inc., Ottawa, Canada) for 10 min, in order to reduce particle size. Cisplatin (5 mM in 10 wt% sucrose, pH 8.0) was added to the liposomes (CHEMS: cisplatin ~1.25 mol/mol) and it was incubated at 37°C for 24 h. The unbound cisplatin was removed by hollow-fiber diafiltration (MicroKros Spectrum Laboratories, Inc., Rancho Dominguez, CA), sterilized by passing them through a 0.45 μm filter (Millipore Corp., Billerica, MA) and then freeze-dried. A schematic diagram of the resulting purified CHEMS liposomes are shown in Fig. 1. The “hollow” CHEMS liposomes were prepared in a similar way but did not contain any cisplatin.

Determination of Size, Zeta Potential and in vitro Tumoricidal Activity

The size distribution of the Lipoplatin™ was determined by dynamic light scattering on Beckman Coulter N+ particle size analyzer and for CHEMS liposomes on a NICOMP Submicron Particle Sizer. All particle size data refer to volume-weighted distributions. The zeta potentials (ζ) of the liposomes were determined on a Zetasizer instrument (Brookhaven Instruments Corp., Holtsville, NY). CHEMS liposomes, at a dose of 15 μg cisplatin per flask, were added to F98 rat glioma cells (CRL-2397, ATCC), propagated in T-75 flasks. Cells were incubated at 37°C for 1, 2, and 4 h, they were then trypsinized and harvested, followed by centrifugation to obtain cell pellets. These were resuspended in 2 ml of phosphate buffered saline (PBS, pH 7.4) and then processed for Pt determinations by means of Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES) at a later date [5]. To assess the in vitro cytotoxicity of free cisplatin, Lipoplatin™ and CHEMS liposomes and their “hollow” counterparts, F98 glioma cells were treated with varying concentrations of either for 4 or 24 hrs. The cells then were plated out in petri dishes, 3 replicates for each concentration and at 7 days the cultures were terminated and colonies were enumerated as previously described [5]. Colonies with >50 cells were enumerated under a dissecting microscope and the surviving fractions (S.F.) were calculated.

Neurotoxicologic Studies

All of the animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and our protocol was approved by the Institutional Animal Care and Use Committee of The Ohio State University (Permit #: A-3261-01 and IACUC protocol number 2007A0261-R1).

Neurotoxicologic studies were carried out in non-tumor bearing male Fischer rats. Initially, a dose escalation study was performed using either Lipoplatin™ or CHEMS liposomes. The former contained 0.45, 0.90, 1.80 or 2.70 μg of cisplatin, respectively, and the latter contained 0.48 μg/μL of cisplatin in 10, 15 and 20 μL. Non-cisplatin containing (“hollow”) liposomes of each type were evaluated as vehicle controls. All of these agents were administered into the striatum of the right cerebral hemisphere by CED over 30 min [3] using a 28 gauge needle as a cannula with 3 animals for each concentration. Those rats that received Lipoplatin™ and did not die acutely were monitored daily and euthanized at 4 d
following CED. Animals that received CHEMS liposomes were monitored clinically and weighed 3X per week until they were euthanized at either 10 or 14 d following administration. The brains of all animals were removed and processed for neuropathologic examination [5].

Biodistribution Studies in F98 Glioma Bearing Rats

The F98 rat glioma was derived from an undifferentiated neoplasm that was induced in the progeny of a pregnant CD Fischer rat that had received an injection of N-ethyl-N-nitrosourea. It has been propagated in vitro and in vivo since 1971 and, as described in a recent review [22], it has been used in a wide variety of studies in experimental neuro-oncology. F98 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT), 100 units/mL penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine. Fischer rats (Animal Production Branch National Cancer Institute, Frederick, MD) weighing 220–240 g were used in the present study. A stereotactic implantation procedure, which has been described in detail elsewhere [23], was employed. F98 cells at a concentration of $10^5$ cells/10 μl in DMEM containing low gelling temperature agarose were injected stereotactically into the right caudate nucleus over 10–15 s through a small entry port of the plastic screw.

Thirteen days later, at which time the tumors had attained volumes of $\approx 25-30$ mm [5], biodistribution studies were initiated. CHEMS liposomes were diluted in normal saline and administered to 8 rats by CED over 30 min (9.6 μg/10 μl). Immediately following or 24 h after CED, 4 rats were euthanized, their brains were removed, the tumors were carefully dissected out from surrounding normal brain and they were weighed, and stored at $-70^\circ$C. Similarly, a 1 mm zone surrounding the excised tumor was dissected out, and this was designated as “brain around

| Lipid Composition | Cisplatin loading (mol/mol) | Loading efficiency | Particle size (nm) | Zeta potential (mV) |
|-------------------|-----------------------------|-------------------|--------------------|---------------------|
| Egg PC:CHEMS:mPEG- | CHEMS: cisplatin 25%       |                   | 55.2±34.3          | $-30.9±0.4^a$       |
| DSPE              | 1 : 2.5 (initial)           |                   | 56.7±20.8          | $-7.9±1.1^b$        |
|                  | 1 : 0.6 (final)             |                   | 52.3±18.2          | $-8.3±0.7^b$        |
| Lipoplatin™       |                             |                   | $-54.7±5^e$        |                     |
| DPPG: SPC-3:      |                             |                   | $-49.6±5^e$        |                     |
| cholesterol:      |                             |                   |                   |                     |
| mPEG-DsPE         |                             |                   |                   |                     |

*Hollow liposomes (before cisplatin loading).
* Liposome/cisplatin measured immediately after preparation.
* After lyophilization, 10 d storage at ambient temperature, and resuspension.
* In water.
* In 5% dextrose.

Figure 1. Schematic representation of a liposome containing CHEMS-cisplatin complexes prepared by the addition of a cisplatin solution to preformed egg PC/CHEMS/mPEG-DSPE liposomes.

doi:10.1371/journal.pone.0048752.g001

Table 1. Formulations of liposomal cisplatin preparations.

doi:10.1371/journal.pone.0048752.t001
Figure 2. Clonogenic survival of F98 glioma cells following treatment with either free cisplatin or liposomal cisplatin for 4 or 24 h. Surviving fractions (S.Fs) were determined for the F98 glioma cells treated with (A) CHEMS liposomes, (B) free cisplatin following a 4 h (●) or 24 h (○) exposure. Each data point represents the mean of 3 replicates ± the standard deviation.

doi:10.1371/journal.pone.0048752.g002


Table 2. Comparison of the toxicity against F98 glioma cells of Lipoplatin™ and CHEMS cisplatin liposomes and their “hollow” counterparts.

| Test agent          | Cisplatin conc (µg/ml) | Surviving fraction (mean ± SD) | P-value* |
|---------------------|------------------------|--------------------------------|---------|
| Lipoplatin™         | 3                      | 0.51±0.13                      | 0.42    |
| “Hollow” Regulon liposomes | 0                    | 0.43±0.05                      |         |
| CHEMS liposomes     | 0.5                    | 0.023±0.003                    | 0.02    |
| “Hollow” CHEMS liposomes | 0                | 0.59±0.13                      |         |

*F98 glioma cells were exposed to the test agent for 4 hours, following which clonogenic assays were carried.

Surviving fractions were determined following 7 days incubation at 37°C in a CO₂ incubator.

*P-value is computed using two-sample t-test.

doi:10.1371/journal.pone.0048752.0022


tumor” (BAT). The remaining right cerebral hemisphere and the left hemisphere were designated “normal” brain. Platinum determinations in all of these tissues were performed at a later date by means of ICP-OES. Based on Pt uptake values, the concentrations of cisplatin (MW 300.05 Da), were calculated by multiplying the Pt values by 1.34. Platinum retention in the F98 glioma after CED of CHEMS liposomes was calculated as % injected dose (ID)/g tumor.

Statistical Evaluation of Data

For data obtained in the in vitro cytotoxicity studies, the means and standard deviations (SD) of surviving fractions of F98 glioma cells were calculated. Data were first log transformed and then fit to a quadratic function. The data also were used to test the difference in S.F. of the cells using a one-way Analysis of Variance (ANOVA), followed by a post hoc test using Tukey’s method [24]. Analysis of the differences in in vitro toxicity of Lipoplatin™ and CHEMS liposomes, and their “hollow” counterparts was determined by means of a two-sample t-test. For the biodistribution data, the means and SD were computed for cisplatin in tumor, brain around tumor (BAT), ipsilateral (tumor bearing) and contralateral (non-tumor bearing) cerebral hemispheres and blood. A two-sample t-test was used to compare Pt concentrations in these tissues at 0 or 24 hours following CED. For retention of Pt in F98 glioma bearing rats, a two-way ANOVA was used to test for differences between free carboplatin and CHEMS liposomes and those between two time points (0 and 24 h). Differences were considered significant if the P value was <0.05.

Results

Preparation and Characterization of CHEMS Liposomes

As a result of the addition of cisplatin, the zeta (ζ) potential of the lipid vesicles decreased from −30.9 mV to −7.9 mV, thereby confirming that it had bound to the liposomes (Table 1). Assuming a uniform distribution of CHEMS on the two sides of the lipid bilayer, the molar ratio of the CHEMS in the outer/inner layer should have been close to 0.6 for the observed liposome size. Based on the procedure that we employed, only the outer layer of the liposomal membrane was accessible for cisplatin and a maximum molar ratio of 1:0.6 was attained for CHEMS/cisplatin liposomes (Table 1). This could either indicate that virtually all CHEMS molecules in the outer lipid layer had reacted with cisplatin or alternatively that coordination compounds had been formed at 1:1 stoichiometry.

In vitro Tumoricidal Activity of Either Free Cisplatin or Cisplatin Containing Liposomes

The in vitro tumoricidal activity of Lipoplatin™ previously has been described in detail elsewhere by Paquette and his research team [25]. Clonogenic survival data for F98 glioma cells that had been exposed to free cisplatin or either Lipoplatin™ or CHEMS liposomes or their “hollow” counterparts at 4 or 24 h are shown in Fig. 2 and Table 2. The IC₅₀ of cisplatin and CHEMS at 4 h were 0.690 and 0.383 µg/mL, respectively, versus 0.335 and 0.259 µg/mL at 24 h. The S.F. of F98 cells were 0.13% following 24 h treatment with CHEMS liposomes containing 0.375 µg/mL cisplatin, versus 0.74% for free cisplatin. Thus, the CHEMS showed more potent cytotoxicity than free cisplatin at 24 h.

It is noteworthy that Lipoplatin™ and its “hollow” counterpart showed equivalent in vitro cytotoxicity against F98 glioma cells (S.F. 0.51 versus 0.43) following a 4 hr incubation. This was attributed to the intrinsic toxicity of the “hollow” liposomes and the slow release of cisplatin from Lipoplatin™. The in vitro cytotoxicity of cisplatin containing CHEMS liposomes was 10× greater than the “hollow” counterpart (S.F. 0.05 versus 0.59). Free cisplatin at a concentration of 3 µg/ml showed the most potent in vitro cytotoxicity (S.F. 0.0002) and this correlated with the marked in vivo neurotoxicity of the free drug (Fig. 3H and 4F).

Neurotoxicologic Studies

Unexpectedly, rats that received the highest doses of Lipoplatin™ (1.8 and 2.7 µg cisplatin) by CED showed acute neurotoxicity, which was manifested as soon as the effects of anesthesia had worn off. These animals clearly were in acute distress, as evidenced by vocalization suggesting that they were in pain, hyperactivity and sensitivity to touch. They were re-anesthetized in the hope that when they again came out of anesthesia, their clinical status would have improved. Since this was not the case, they then were euthanized. The brains of these animals showed one or more foci of acute hemorrhage (Fig. 3A) at sites other than along the needle track. Rats that received Lipoplatin™, containing 0.9 or 0.45 µg of cisplatin, which were euthanized 4 days following administration, showed a spectrum of changes ranging from mild to severe with hemorrhage, extensive necrosis, with or without infiltrates of foamy macrophages (Fig.3B and C). Rats that received the “hollow” counterparts of Lipoplatin™ clinically did not appear to be sick. However, the brains of these animals, euthanized d 4 following administration, showed hemorrhage with associated necrosis, edema of the neuropil and an infiltrate of macrophages (Fig. 3D and E). In summary, Lipoplatin™ and its “hollow” counterpart proved to be highly neurotoxic when administered i.e. by CED at these doses. This in part was due to the intrinsic toxicity of the liposomes themselves, together with the neurotoxic effects of cisplatin itself.

In contrast, the brains of half of the rats that received CHEMS liposomes at doses of 4.8, 7.2 or 9.6 µg of cisplatin showed minimal histopathologic abnormalities at 7 wks following administration. In some animals there were focal accumulations of clear vacuoles that presumptively may have contained lipid (Fig. 4A), and in others there were scattered reactive astrocytes and astrogliosis with necrosis and incipient necrosis, infiltrates of macrophages (Fig. 4B), and evolving reactive eosinophilic neurons, which were consistent with late neuronal injury. In a second study with CHEMS liposomes, containing 3, 6 or 9 µg of cisplatin rats were euthanized at d 10 following administration by CED. Again, there was a spectrum of changes ranging from normal in the...
brains of some rats, and focal areas of hemorrhage in others that received the lowest dose, to focal accumulations of lymphocytes and macrophages (6 μg of cisplatin) to focal areas of intense inflammation (Fig. 4C and D) with large numbers of lymphocytes and macrophages, hemorrhage (Fig. 4C) and prominent neovascularization (Fig. 4E) and necrosis (9 μg). Based on these findings, it was concluded that the 3, 4.8 or 6 μg doses of cisplatin of the CHEMS liposomes appeared to be reasonably well tolerated.
following i.c. CED although there were a variety of neuropathologic findings ranging from none to moderate. On the other hand, the 9 μg dose produced severe neuropathologic changes.

The brains of rats that received “hollow” CHEMS liposomes, which were euthanized at d 10 following administration, showed prominent necrosis with an intense inflammatory response consisting of lymphocytes and macrophages (Fig. 4F). Immunostaining for glial fibrillary acidic protein (GFAP) revealed foci of reactive astrogliosis in the paraventricular area (Fig. 4G). The brains of rats that received either 6 or 3 μg of free cisplatin, which were euthanized on d 7, showed the most severe changes of any that were seen in the present study. These included prominent confluent areas of hemorrhage with white matter necrosis (Fig. 4H), infiltrates of macrophages and early fibrin deposition in the walls of blood vessels (Fig. 3F).

### Biodistribution and Tumor Retention of Liposomal Cisplatin in F98 Glioma Bearing Rats

The amounts of platinum retained in the brain tumors of rats were 46.6±4.2% at 1 h following CED of CHEMS liposomes and 26.6±1.2% at 24 h. The tumor concentration was 4.4 μg/g immediately following CED of CHEMS liposomes containing 9.6 μg of cisplatin and 2.8 μg/g at 24 h (P = 0.05, Table 3). This was significantly higher (P = 0.05) than the drug concentrations in normal brain (0.1 to 0.8 μg/g). The tumor Pt concentration was comparable to that determined following CED of carboplatin when adjusting for the higher dose of the latter [5]. Furthermore, based on these studies [5], the concentrations in extracranial tissues would have been in the undetectable range (<0.01 μg/g).

### Discussion

The purpose of the present study was to evaluate two liposomal formulations of cisplatin as potential candidates for future in vivo therapeutic studies using the F98 rat glioma model. The first, Lipoplatin™, was found to be highly neurotoxic following i.c. CED to non-tumor bearing Fischer rats. Therefore, we designed, prepared and characterized a novel liposomal carrier with the cisplatin bound to CHEMS as a ligand in the outer lipid layer. This formulation addressed two common problems associated with liposomal drug delivery, the efficiency of encapsulation and drug release [26]. Failure of the liposomes to release the encapsulated drug would compromise its therapeutic efficacy. To obviate this problem, cisplatin was added to the CHEMS liposomes after their preparation in order to allow for the cisplatin-CHEMS complex to form on the outer lipid layer. The residual negative ζ potential of the nanoparticles possibly was due to the negative charge of the mPEG-DSPF conjugate.

The acute neurotoxicity of Lipoplatin™ and the “hollow” counterpart was completely unexpected since Lipoplatin™ has been shown to be safe and therapeutically effective following i.v. infusion in patients with NSCLC [8,9]. Extensive in vitro [25] and in vivo [27] studies on Lipoplatin™ have been carried out by Paquette and his research team using the F98 glioma model. Lipoplatin™ showed only a slight reduction in in vitro tumoricidal activity compared to low concentrations of free cisplatin, and that this was enhanced when it was combined with X-irradiation [25]. Based on these promising results, in vivo studies were initiated with Lipoplatin™ and Lipoxal™, which contained oxaplatin [27]. These were administered to F98 glioma bearing rats by intracarotid infusion either alone or in combination with a single 15 Gy dose of X-irradiation. Animals that received Lipoplatin™ showed a marked reduction in toxicity compared to cisplatin, and the MST was 30.2 d, compared to 22.0 d for untreated controls and 13.3 d for cisplatin treated rats whose deaths were attributable to drug toxicity. However, as reported by Ellegaard and her research team [28,29], free cisplatin administered by i.c. CED (6 μg in 20 μL) to F98 glioma bearing rats, resulted in a MST of 59 d with a 13% cure rate with no clinical evidence of neurotoxicity compared to a MST of 24 d for untreated controls. However, neuropathologic studies to determine the toxicity of cisplatin were not carried out and based on our own observations; we would expect that this would have produced neurotoxic effects. Even better results have been obtained by i.c. CED of carboplatin in combination with 6 MV photons [5,30–32] without any histopathologic evidence of neurotoxicity [5]. As we have shown in the present study, free cisplatin at doses of either 3 or 6 μg produced severe neuropathologic changes consisting primarily of hemorrhage and necrosis at the site of administration. This is in...
striking contrast to the minimal neuropathologic changes observed, following i.c. CED of 20 μg carboplatin or infusion by means of Alzet osmotic pumps (84 μg) [3].

Carboplatin is subject to import mechanisms through the cell membrane using copper transporters limiting its cytoplasmic uptake [7], whereas its formulation into Lipoplatin™ appears to yield nanoparticles that greatly enhance its cytoplasmic uptake through fusion with the cell membrane or by endocytosis [10]. The fusogenic properties of Lipoplatin™ along with its tumor concentration after i.v. administration to patients, resulted in a 40-fold higher concentration in tumors compared to adjacent normal tissues in surgically resected specimens obtained from patients with NSCLC [6]. This resulted in a significant increase in its therapeutic efficacy [9]. However, as shown in the present study, its fusogenic properties may make it unsuitable for direct i.c. CED to the brain. The acute neurotoxicity observed almost immediately following the administration of Lipoplatin™ and its hollow liposome counterparts, which consisted of pain and hypersensitivity to touch, may have been due to cerebral edema and hemorrhage. Intravenous administration of Lipoplatin™ to treat brain tumors is currently under investigation and animal studies suggest that it crosses the BBB to a greater extent than free cisplatin (Boulikas, unpublished data).

There is very little in the neuropathology [33], neurotoxicology [34,35] and nanotoxicology literature [36,37] relating to the neurotoxic effects of drug containing liposomes administered i.c. by CED. Liposomal size and shape are critical determinants as to whether they can traverse the BBB [38]. Direct i.c. CED completely bypasses the BBB, and therefore, particle size may have been less important. However, surface composition and physical properties such as charge and ζ potential and their drug payload can be of critical importance in determining whether they will have a direct neurotoxic effect and the former may explain the neurotoxicity of the “hollow” liposomes. The minimal neuropathologic changes seen within the brains of rats dying immediately following i.c. by CED of Lipoplatin™, and the severity of their acute neurologic symptoms suggest that acute cerebral edema was responsible. The changes seen in the brains of animals that were euthanized at 4 d following administration suggest that these were due to direct toxic effects on gray and white matter, which possibly may have been due to oxidative stress [10].

Turning to the neuropathologic changes seen following i.c. CED of CHEMS liposomes and their “hollow” counterparts liposomes in the present study, these ranged from none to moderate to severe for both the lower and higher dose. These may have been due to either the rapid or slow release of cisplatin in the case of the former, combined with the intrinsic toxicity of the CHEMS “hollow” liposomes. These findings precluded carrying out any therapy studies in F98 glioma bearing rats.

Bankiewicz and Dickinson [12-16,20] and their respective research teams, have had the most experience of any investigators who have administered drug containing liposomes i.c. by CED. Most recently, they have evaluated CPT-11 (Irinotecan) containing liposomes in canines with spontaneous intracranial tumors. There was clear evidence of therapeutic efficacy, as determined by imaging studies that revealed a reduction in tumor volume, the presence of tumor necrosis and a change in tumor morphology consistent with a drug effect without any evidence of toxicity. Kawabata and his research team recently have evaluated sodium borocaptate, containing transferrin targeting liposomes, which were administered i.c. by CED, as potential boron delivery agents for neutron capture therapy of F98 glioma bearing rats [39]. These liposomes, which also contained an iodine contrast agent, were well tolerated clinically and imaging studies revealed precise localization at the site of the tumor with delivery of a high boron payload. However, no neuropathologic studies were carried out to determine if they were neurotoxic. Similarly, Brenner and his research team recently have evaluated rhenium-186 containing liposomes, which also were administered i.c. by CED to U87 glioma bearing rats [40]. The endpoint of these studies was prolongation of median survival time, which was significantly increased compared to that of rats that received non-radioactive liposomes with minimal neurotoxicity.

All of these studies suggest that i.c. CED of liposomes may have therapeutic efficacy. However, we do not believe that therapy studies with Lipoplatin™ or cisplatin containing CHEMS liposomes are warranted at this time, especially since such good survival data have been obtained in the F98 glioma model using CED or Alzet pump delivery of free carboplatin [5,27,28]. Our findings suggest that further refinements in the design and formulation of cisplatin containing liposomes will be required before they can be administered i.c. by CED for the treatment of brain tumors and that a formulation, such as Lipoplatin™, which may be safe when given systemically, may be highly neurotoxic when administered directly into the brain. Liposomal formulations of other cytoreductive therapeutic agents for the treatment of cancer [41], and more specifically of brain tumors, may have certain advantages [20]. However, at this point in time no such agents have been used clinically. Further studies using them are being pursued and it remains to be determined if indeed they will have clinical utility.

Acknowledgments

We thank Dr. Paul Wakely for assistance in taking photomicrographs, Mrs. Heidi Bosworth for expert secretarial assistance in the preparation of this manuscript and Dr. Benoît Paquette for sharing recently published data [27] with us prior to their publication.

Author Contributions

Performed the experiments: TH WY RFB ARC LA RK BT. Analyzed the data: TH RFB WY RJN KK BT TB HE. Contributed reagents/materials/analysis tools: TB. Wrote the paper: RFB WY TH RK BT RJL. Contributed to the design of the experiments: TH. Carried out in vitro studies: TH RJN. Assisted in the writing of the manuscript: TH. Carried out statistical analyses: TH. Contributed to the design of in vitro and in vivo studies: RFB. Carried out neuropathologic examination of all brain sections: RFB. Contributed to the design of and carried out in vivo studies: WY. Contributed to the writing of the Materials & Methods and Results: WY. Prepared and characterized CHEMS liposomes with the advice of RJL. Contributed to the writing of the section on neuropathologic studies: ARC LA. Provided Lipoplatin™ and “hollow” Lipoplatin™ TM liposomes: TB. Contributed to the writing of the manuscript: TB HE. Carried out studies on intracerebral convection enhanced delivery of cisplatin in tumor bearing rats which laid the groundwork for the present study: HE.

References

1. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573–584.
2. Huaain K, Whitworth C, Rybak LP (2004) Time response of carboplatin-induced nephrotoxicity in rats. Pharmacol Res 50: 291–300.
3. Siddik ZH, Boxall FE, Harrapp KR (1987) Hematological toxicity of carboplatin in rats. Br J Cancer 55: 373–379.
4. McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8: 10–16.
5. Yang W, Huo T, Barth RF, Gupta N, Weldon M, et al. (2011) Convective enhancement of delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. J. Neurooncol 101: 379–390.

6. Boulkas T, Stathopoulos GP, Volokhina N, Vongkouska M (2005) Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. 25: 3031–3039.

7. Boulkas T (2009) Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin. Exp. Opinion. Investig. Drugs 18: 1197–210.

8. Stathopoulos GP, Antoniou D, Dimitrakis J, Michalopoulos P, Basta A, et al. (2010) Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann. of Oncology 21: 2227–2232.

9. Stathopoulos GP, Antoniou D, Dimitrakis J, Stathopoulos J, Marosio K, et al. (2011) Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol. 68: 943–950.

10. Stathopoulos GP and Boulkas T (2012) Lipoplatin formulation review article. J Drug Delivery 2012. doi:10.1155/2012/501963.

11. Wittgen BPH, Kunst PWA, van der Born K, van Wijk AW, Perkins W, et al. (2007) Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res.13: 2414–2421.

12. Saito R, Bringas JR, McKnight TR, Wendlund MF, Mamot C, et al. (2004) Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64: 2572–2579.

13. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, et al. (2004) Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 68: 1–9.

14. Agrawal RM, Kello AP, Martin AJ, Larson PS, Starr PA, et al. (2013) Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct. Neurosurg 89: 141–151.

15. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, et al. (2008) Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging. J. Neurosurg 108: 989–996.

16. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Larson RF, et al. (2010) Canine spontaneous glioma: a translational model system for convection-enhanced delivery. J. Neurooncol 12: 929–940.

17. Hamers HI, de Kroon AIPM (2007) Nanocapsules: a novel lipid formulation platform for platinum-based anti-cancer drugs. J. Liposome Res.17: 183–189.

18. Miltown LL, Sousain C, Jahnke K, Johanson C, Siegal T, et al. (2007) Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 13: 2414–2421.

19. Hall WA (2009) Convection-enhanced delivery: neurosurgical issues. Current Drug Targets 10: 126–130.

20. Barth RF and Kaur B (2009) Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BTCA, ST2, and CNS-1 gliomas. J. Neurooncol 94: 299–312.

21. Yang W, Barth RF, Carpenter DE, Mosechberger ML, Goodman, JH (1996) Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery 38: 985–992.